Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab.

Literature DB >> 31004017

Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab.

Lucy B M Cook^1,2,3, Maria Antonietta Demontis⁴, Sophie Sagawe¹, Aviva Witkover¹, Anat Melamed¹, Jocelyn Turpin¹, Richard Dillon⁵, Jana Haddow³, Alexandra J Marks², Charles R M Bangham¹, Paul Fields⁵, Graham P Taylor^1,3, Aileen G Rowan⁶.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2019 PMID： 31004017 PMCID： PMC6959161 DOI： 10.3324/haematol.2019.219253

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

15 in total

1. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

Authors: Takashi Ishida; Tatsuro Joh; Naokuni Uike; Kazuhito Yamamoto; Atae Utsunomiya; Shinichiro Yoshida; Yoshio Saburi; Toshihiro Miyamoto; Shigeki Takemoto; Hitoshi Suzushima; Kunihiro Tsukasaki; Kisato Nosaka; Hiroshi Fujiwara; Kenji Ishitsuka; Hiroshi Inagaki; Michinori Ogura; Shiro Akinaga; Masao Tomonaga; Kensei Tobinai; Ryuzo Ueda
Journal: J Clin Oncol Date: 2012-02-06 Impact factor: 44.544

2. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones.

Authors: Nicolas A Gillet; Nirav Malani; Anat Melamed; Niall Gormley; Richard Carter; David Bentley; Charles Berry; Frederic D Bushman; Graham P Taylor; Charles R M Bangham
Journal: Blood Date: 2011-01-12 Impact factor: 22.113

3. Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases.

Authors: Maria A Demontis; Silva Hilburn; Graham P Taylor
Journal: AIDS Res Hum Retroviruses Date: 2012-09-25 Impact factor: 2.205

4. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

Authors: Kazuhito Yamamoto; Atae Utsunomiya; Kensei Tobinai; Kunihiro Tsukasaki; Naokuni Uike; Kimiharu Uozumi; Kazunari Yamaguchi; Yasuaki Yamada; Shuichi Hanada; Kazuo Tamura; Shigeo Nakamura; Hiroshi Inagaki; Koichi Ohshima; Hitoshi Kiyoi; Takashi Ishida; Kouji Matsushima; Shiro Akinaga; Michinori Ogura; Masao Tomonaga; Ryuzo Ueda
Journal: J Clin Oncol Date: 2010-02-22 Impact factor: 44.544

5. Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma.

Authors: Lucy B Cook; Aileen G Rowan; Maria A Demontis; Sophie Sagawe; Nicolas A Gillet; Anat Melamed; Claire Greiller; Aviva Witkover; Charles R M Bangham; Graham P Taylor
Journal: Int J Hematol Date: 2017-10-31 Impact factor: 2.490

6. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells.

Authors: Osamu Yoshie; Ryuichi Fujisawa; Takashi Nakayama; Hitomi Harasawa; Hideaki Tago; Dai Izawa; Kunio Hieshima; Youichi Tatsumi; Kouji Matsushima; Hitoshi Hasegawa; Akihisa Kanamaru; Shimeru Kamihira; Yasuaki Yamada
Journal: Blood Date: 2002-03-01 Impact factor: 22.113

7. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.

Authors: Takashi Ishida; Atae Utsunomiya; Shinsuke Iida; Hiroshi Inagaki; Yoshifusa Takatsuka; Shigeru Kusumoto; Genji Takeuchi; Shigeki Shimizu; Masato Ito; Hirokazu Komatsu; Atsushi Wakita; Tadaaki Eimoto; Kouji Matsushima; Ryuzo Ueda
Journal: Clin Cancer Res Date: 2003-09-01 Impact factor: 12.531

8. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.

Authors: Takashi Ishida; Atae Utsunomiya; Tatsuro Jo; Kazuhito Yamamoto; Koji Kato; Shinichiro Yoshida; Shigeki Takemoto; Hitoshi Suzushima; Yukio Kobayashi; Yoshitaka Imaizumi; Kenichi Yoshimura; Kouichi Kawamura; Takeshi Takahashi; Kensei Tobinai; Ryuzo Ueda
Journal: Cancer Sci Date: 2017-08-28 Impact factor: 6.716

Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab.

1. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

2. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones.

3. Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases.

4. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

5. Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma.

6. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells.

7. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.

8. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.

9. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma.

10. The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma.

1. HTLV-1 as a Model for Virus and Host Coordinated Immunoediting.

Review 2. Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma.

3. A new paradigm for the management of ATL.